The identification of novel genetic modifiers of age-at-onset (AAO) of Alzheimer's disease (AD) could advance our understanding of AD and provide novel therapeutic targets. A previous genome scan for modifiers of AAO among families affected by early-onset AD caused by the PSEN2 N141I variant identified 2 loci with significant evidence for linkage: 1q23.3 and 17p13.2. Here, we describe the fine-mapping of these 2 linkage regions, and test for replication in 6 independent datasets. By fine-mapping these linkage signals in a single large family, we reduced the linkage regions to 11% their original size and nominated 54 candidate variants.
| INTRODUCTION
Alzheimer's disease (AD) explains the diagnosis of dementia in >70% of persons aged ≥80 years. 1 AD is characterized by the deposition of amyloid (Aβ) plaques and neurofibrillary tangles in the brain, resulting in progressive dementia. 2 Rare variants in APP, PSEN1 and PSEN2 cause a highly penetrant autosomal dominant form of early-onset AD (EOAD). The APOE ε4 allele is strongly associated with increased risk of late-onset AD (LOAD), and several other loci are associated with small but significant effects 3 in genome-wide associations studies (GWAS).
The identification of genetic modifiers of age-at-onset (AAO) of AD offers promise for both a better understanding of AD biology and new potential interventions. Variants that affect AAO of AD can be considered AD risk or protective variants, as reduced (or increased) AAO means greater (or lower) chance of becoming affected before death from other causes. AAO modifiers identified in EOAD families are likely to be relevant to LOAD due to their shared biology.
Although the boundary between EOAD and LOAD is typically defined near age 65 years, familial AD is not discretely divided into these 2 categories. Families segregating dominant EOAD variants may include relatives affected by LOAD, 4, 5 while multiplex families affected by LOAD may include relatives affected prior to the age of 65 years. [6] [7] [8] The shared genetic basis of EOAD and LOAD has been showed by targeted sequencing analyses, where AD risk variants in probands ascertained from LOAD families have been identified. 9 Furthermore, APOE, the most well-established genetic modifier of AAO of AD, influences AAO of AD in families affected by EOAD 5, 10, 11 and persons affected by LOAD. 12 AAO of AD is heritable, and much of that heritability remains to be explained. Heritability estimates for AAO of AD from twin studies range from 57% to 78%, suggesting the presence of genetic modifiers. 13, 14 Variation in APOE is estimated to only explain between 4% and 15% of the genetic variance in AAO of AD. [15] [16] [17] [18] Association testing within candidate genes, 19 GWAS 12, 20 and linkage studies 4, 5, 8 have found evidence for additional modifiers of AAO of AD in samples with and without causal EOAD variants. Several of these loci are significant or suggestive across independent genomescans for AAO modifiers, including 5q15, 21, 22 7q31.33, 5, 6, 23 8p22, 12, 24 9q33.1, 6, 23 13q33.3 12, 21 and 20p12.3. 23, 25 One of these loci, 7q31.33, is supported by analyses of Volga German PSEN2 families affected by EOAD 5 and independent LOAD datasets with European ancestry. 6, 23 Additional research, including fine-mapping and functional studies, is needed to identify the AAO modifiers within these loci.
We have previously provided strong evidence for the existence of genetic modifiers of AAO on chromosomes 1q23.3 and 17p13.2 in Volga German EOAD families sharing a founder causal variant in PSEN2. 5 Each of these linkage signals were driven by a single large pedigree, the R family, with a range of AAO of AD spanning 40 years.
Here, we fine-map these 2 linkage regions within the R family, identify the sequence variants driving these signals, and provide independent evidence of association between AAO of AD and variants within NCSTN and ZBTB4.
| MATERIALS AND METHODS

| Discovery dataset
The R family possessed significant evidence for linkage between AAO of AD and both 1q23.3 and 17p13.2 after adjustment for the Volga German PSEN2 variant and APOE genotype. 5 AAO of AD spanned 4 decades within this 65-member family (Table 1) , including at least 2 cases without the PSEN2 N141 allele. Dense SNP genotypes were generated for the 32 most informative relatives using the Illumina HumanOmni1 SNP array by the Northwest Genomics Center (NWGC) at the University of Washington. Six informative relatives were selected for whole-exome sequencing (WES), and wholegenome sequencing (WGS) was performed on 4 of these by the NWGC using the same bioinformatics pipeline (Appendix S1, Supporting Information). Candidate variants were genotyped in all available relatives using a TaqMan SNP Genotyping Assay from ThermoFisher (Waltham, Massachusetts) where possible, or else
Sanger sequencing (Table S1 ).
The Germans from Russia (GFR, (Tables S3;   Appendix S1 ). We excluded variants missing ≥20% of genotypes, which efficiently separated the concordant vs discordant variants when smMIPs and traditional genotypes were compared (Table S4 , Figure S1 ). The study protocol was approved by the University of Washington Institutional Review Board, and informed consent was obtained for all participants.
| Replication datasets
Six independent AD datasets were used for the replication phase ( The replication datasets were drawn from admixed populations or populations with geographic structure, and required association methods incorporating estimates of kinship and population structure (Table 1) . Within each replication dataset, kinship was estimated empirically using KING. 46 Samples with pedigree errors were removed, and evidence of cryptic relatedness (kinship >0.1) was noted. AAO of AD was adjusted for the count of APOE ε2 and APOE ε4 alleles using a Cox proportional hazards model. Principal components (PCs) were estimated by PC-Air, 47 and a genetic relatedness matrix (GRM) was built by PC-Relate 48 which adjusted the GRM for PCs 1 and 2. Association testing was performed using a linear mixed model adjusting for this GRM and PCs 1 and 2 within the GENESIS software package. 49 The skewed distribution of Martingale residuals is inappropriate for this linear mixed model, and so the deviance residuals were analyzed as a quantitative trait with a normal distribution. The number of independent tests within each dataset were estimated using GEC v0.2.
50
Cox proportional hazards analyses evaluated the direction of effect of candidate variants, adjusting for the same covariates as the AAO of AD phenotype. Alternative models for modeling APOE as a covariate had minimal effects on the mean squared error (Table S5) .
3 | RESULTS
| The discovery dataset
The MG approach combined with estimates of IBD to dramatically narrow both linkage regions observed in the R family. We identified 11 topSNPs on chr1 and 28 topSNPs on chr17 which best explained the evidence for linkage on each chromosome (<1st percentile for BF, >99th percentile for size, Figure 1 , Tables S6, S7 ). The risk alleles at topSNPs (Table S7) (Table S2) . Most of these variants were not captured in the WES data and are noncoding.
Eleven variants were nominally associated with AAO in both the R family and the entire GFR sample (P < .05, 52 Variant rs71370498 is also predicted to alter 6 transcription factor binding site (TFBS) motifs, 52 suggesting a mechanism by which the variant could influence the expression of ZBTB4. This variant is significantly associated with AAO of AD in the GFR, after adjustment for the number of independent tests (P < .005), and the alternate allele at rs71370498 significantly increases the hazard of AD among the GFR (z = 2.06, P = .039). The NCSTN variant rs73029438 also falls within a conserved promoter ( ENSR00000019473 51 ), bears the corresponding histone modification and DHS in >20 tissues, and is predicted to alter TFBS motifs. 52 The alternate allele tended to increase the hazard of AD among the GFR, although the effect was not significant (z = 0.903, P > .05).
| Independent replication of GFR loci
Association testing of SNPs shared by 5 independent datasets replicated association between ZBTB4 and AAO of AD, while none of the SNPs surrounding NCSTN were significant (Table 3) . Three SNPs, rs2302761, rs2302762, and rs8071847, were significantly associated with AAO of AD in a meta-analysis of the Hispanic datasets after correcting for the number of independent tests on chr17 (P < .0081, Table 3 ). One of these SNPs, rs2302762, was also nominally associ- Association testing of exome variants among the ADSP WES dataset found nominally significant evidence of association between AAO of AD and multiple SNPs in ZBTB4 and a single SNP in NCSTN (Table 4, Table S9 ). Three of the 5 ZBTB4 SNVs nominally associated with AAO of AD (P < .05) were missense variants, as was the single NCSTN SNV. 51 The NCSTN SNV, rs200632380, falls within the same promoter as rs73029438, 51 the SNP associated with AAO of AD among the GFR. The associated SNVs were rare, as all but rs11871207 were observed in a single individual. These tests were also well controlled, with λ = 0.9934. The association between AAO of AD and both promoter variants and eQTLs in independent datasets reinforces the potential role of regulatory variants in the AAO of AD. We show below that both ZBTB4
| DISCUSSION
and NCSTN are connected to known AD biology, nominating specific molecular and cellular mechanisms that may influence AAO of AD.
ZBTB4 can be connected to AD pathogenesis via Aβ and cell death pathways. ZBTB4 is a zinc finger protein family member which acts as a transcriptional repressor 55 and plays an important role in the regulation of cell cycle. 56 Aβ exposure degrades HIPK2 and increases the amount of unfolded p53 in AD tissues. [57] [58] [59] This interaction has been proposed to lead to the pathogenesis of AD. 59 It is possible ZBTB4 could alter the pathogenesis of AD, as the degradation of HIPK2 causes increased ZBTB4 expression 56 and ZBTB4 suppresses the apoptotic response to p53 activation. 60 Furthermore, animal models suggest that ZBTB4 expression can influence agerelated cognitive impairment, as rats that are not cognitively impaired by aging have upregulated ZBTB4. 61 This suggests that variants altering ZBTB4 expression and/or regulation may influence AD through mechanisms related to cell cycle and apoptosis.
NCSTN is part of the gamma secretase complex along with PSEN1 and PSEN2, 2 EOAD genes. 62 Alterations in NCSTN expression levels influence the production of the Aβ intrinsic to the pathology of AD. 63, 64 The GFR variant rs73029438 falls within the same NCSTN ). These results suggest that it may be through the alteration of Aβ production that variants influencing NCSTN may influence the pathogenesis of the disease.
In addition to the ZBTB4 and NCSTN promoter variants, several additional variants on the linked haplotypes in the R family were also nominally associated with AAO of AD in the GFR (Table 2) . It is possible that the cumulative effects of these variants contribute to the proportion of variance in AAO of AD explained by the linked haplotypes. This would be consistent with the eQTL and complex trait literature in humans 69, 70 and model organisms. 71, 72 It is therefore noteworthy that the Aβ and cell cycle/death pathways implicated by NCSTN and ZBTB4 are influenced by the variable expression of several of the additional genes associated with AAO of AD among the GFR: KDM6B, 73 NOS1AP, 74 and ATF6. 75 The coding and regulatory consequences of the variants associated with AAO of AD provide strong gene targets for the next stage of functional analyses.
Their shared pathways may be used to define cellular and molecular phenotypes to test for association with either candidate variants or AAO of AD.
We have reduced linkage regions to their underlying haplotypes, and prioritized variants within them. Our strongest evidence of association with AAO of AD across multiple datasets implicates both regulatory and missense variants in ZBTB4. Although our association testing was blind to the function of the associated genes, the function of both ZBTB4 and NCSTN can be directly and indirectly linked to AD risk and pathology. Future bioinformatics annotation and functional assays will be performed to determine how each variant influences the target gene, and whether these effects are independent. This may yield insight that can be leveraged into new therapeutic agents.
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